| Summary of Basic Net Income (Loss) Per Share of Class A and Class B Common Stock |
The following table sets forth the computation of net income attributable to the Company used to compute basic net income per share of Class A and Class B common stock for the three and six months ended June 30, 2025 and 2026.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
$ |
8,827 |
|
|
$ |
22,121 |
|
|
$ |
18,100 |
|
|
$ |
|
|
Less net income (loss) attributable to non-controlling interests |
|
|
(203) |
|
|
|
249 |
|
|
|
(378) |
|
|
|
498 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to Guardian Pharmacy Services, Inc. |
|
$ |
9,030 |
|
|
$ |
21,872 |
|
|
$ |
18,478 |
|
|
$ |
35,167 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Summary of Basic and Diluted Net Income Per Share of Class A and Class B Common Stock |
The following table sets forth the computation of basic and diluted net income per share of Class A and Class B common stock (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income per share attributable to common
stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allocation of net income attributable to Guardian |
|
$ |
17,196 |
|
|
$ |
4,676 |
|
|
$ |
24,078 |
|
|
$ |
11,089 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares of Class A and Class B common stock outstanding |
|
|
49,787 |
|
|
|
13,539 |
|
|
|
43,357 |
|
|
|
19,967 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income per share attributable to common stockholders |
|
$ |
0.35 |
|
|
$ |
0.35 |
|
|
$ |
0.56 |
|
|
$ |
0.56 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income per share attributable to common stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allocation of net income attributable to Guardian |
|
$ |
17,196 |
|
|
$ |
4,676 |
|
|
$ |
24,078 |
|
|
$ |
11,089 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares used in basic computation |
|
|
49,787 |
|
|
|
13,539 |
|
|
|
43,357 |
|
|
|
19,967 |
|
Dilutive Restricted Stock Units and Class A and B |
|
|
400 |
|
|
|
109 |
|
|
|
297 |
|
|
|
137 |
|
Weighted average shares of Class A and Class B common stock outstanding used to calculate diluted net income per |
|
|
50,187 |
|
|
|
13,648 |
|
|
|
43,654 |
|
|
|
20,104 |
|
Diluted net income per share attributable to common |
|
$ |
0.34 |
|
|
$ |
0.34 |
|
|
$ |
0.55 |
|
|
$ |
0.55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
June 30, 2025 |
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income per share attributable to common stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allocation of net income attributable to Guardian Pharmacy Services, Inc. |
|
$ |
3,262 |
|
|
$ |
5,768 |
|
|
$ |
4,805 |
|
|
$ |
13,673 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares of Class A and Class B common stock outstanding |
|
|
22,412 |
|
|
|
39,634 |
|
|
|
16,134 |
|
|
|
45,910 |
|
Basic net income per share attributable to common stockholders |
|
$ |
0.15 |
|
|
$ |
0.15 |
|
|
$ |
0.30 |
|
|
$ |
0.30 |
|
Diluted net income per share attributable to common stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allocation of net income attributable to Guardian Pharmacy Services, Inc. |
|
$ |
3,262 |
|
|
$ |
5,768 |
|
|
$ |
4,805 |
|
|
$ |
13,673 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares used in basic computation |
|
|
22,412 |
|
|
|
39,634 |
|
|
|
16,134 |
|
|
|
45,910 |
|
Dilutive Restricted Stock Units and Class A and B Common Stock |
|
|
418 |
|
|
|
739 |
|
|
|
263 |
|
|
|
748 |
|
Weighted average shares of Class A and Class B common stock outstanding used to calculate diluted net income per share |
|
|
22,830 |
|
|
|
40,373 |
|
|
|
16,397 |
|
|
|
46,658 |
|
Diluted net income per share attributable to common stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|